Danaher’s $9.9B Masimo Deal Marks One of 2026’s Largest Medtech Buyouts

Danaher (DHR) is acquiring Masimo for $9.9B at $180 per share. This represents a 40% premium.

Masimo shares jumped 30.27% toward the deal price. Danaher stock fell 6.09% on integration concerns.

Masimo posted Q3 non-GAAP EPS of $1.32, up 38% year-over-year after selling its consumer audio division.

A recent study identified one single habit that doubled Americans’ retirement savings and moved retirement from dream, to reality. Read more here.

Danaher (NYSE: DHR) is acquiring Masimo (NASDAQ: MASI) for $9.9 billion in an all-cash deal that values the medical technology company at $180 per share. The transaction, announced February 17, 2026, represents a nearly 40% premium over Masimo’s closing price on Friday, February 13, 2026.

Masimo specializes in pulse oximetry and patient monitoring technology, generating $2.18 billion in revenue over the trailing 12 months. The company reported $371.5 million in revenue for Q3 2025, with non-GAAP EPS of $1.32, up 38% year-over-year. Masimo recently streamlined operations by selling its Sound United consumer audio division, allowing management to refocus on core medical device business.

This acquisition follows Danaher’s playbook of adding high-quality diagnostics and life sciences assets. With $24.57 billion in trailing revenue and $7.14 billion in EBITDA, Danaher has the financial capacity to absorb this deal, which represents approximately 6.8% of its $145.88 billion market cap. Management expects the transaction to be accretive to earnings, with significant synergies anticipated.

Masimo shares jumped 30.27% over the past week to $174.69, approaching the deal price. Meanwhile, Danaher shares dropped 6.09% over the same period to $206.36, reflecting investor concerns about dilution and integration costs. The deal requires Masimo shareholder approval and regulatory clearance, with closing expected in the second half of 2026.

Danaher is expanding its medical device footprint with this acquisition. Masimo shareholders will receive $180 per share in cash, representing a nearly 40% premium over the February 13, 2026, closing price, pending deal approval and regulatory clearance.

Most investors are forced to guess how the market will react to news rather than trading the news itself. Kalshi flips that model by letting you trade directly on real world outcomes like interest rates, inflation prints, recessions, and the results are shocking.

Each market is simple. You predict whether something will happen or not. If you are right, the contract pays out. Everyday people are printing money based on things they already know, and having a blast at the same time. Read more here.